CVS Health (NYSE:CVS) was upgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm presently has a $90.00 target price on the pharmacy operator’s stock. Raymond James Financial’s target price would indicate a potential upside of 14.72% from the company’s previous close. The analysts noted that the move was a valuation call.
CVS has been the subject of several other research reports. Royal Bank of Canada started coverage on CVS Health in a research report on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 target price for the company. Jefferies Group increased their target price on CVS Health from $82.00 to $86.00 and gave the stock a “hold” rating in a research report on Friday, September 15th. Needham & Company LLC reissued a “hold” rating on shares of CVS Health in a research report on Sunday, September 10th. Oppenheimer reissued a “buy” rating and issued a $95.00 target price on shares of CVS Health in a research report on Monday, October 9th. Finally, Mizuho set a $90.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. CVS Health has an average rating of “Buy” and a consensus price target of $86.42.
CVS Health (CVS) traded up $3.32 during midday trading on Thursday, reaching $78.45. The company’s stock had a trading volume of 14,241,000 shares, compared to its average volume of 10,420,000. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The stock has a market cap of $79,470.00, a PE ratio of 16.21, a P/E/G ratio of 1.38 and a beta of 0.90.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.61% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of CVS. Fieldpoint Private Securities LLC increased its holdings in shares of CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares in the last quarter. Wealthcare Advisory Partners LLC increased its holdings in shares of CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares in the last quarter. Arcadia Investment Management Corp MI increased its holdings in shares of CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of CVS Health in the 2nd quarter worth $119,000. Finally, Gemmer Asset Management LLC increased its holdings in shares of CVS Health by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares in the last quarter. 81.63% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Raymond James Financial Upgrades CVS Health (CVS) to Strong-Buy” was reported by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/07/raymond-james-financial-upgrades-cvs-health-cvs-to-strong-buy.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.